Alan L. Hinderliter, MD a, ⁎ , Park W. Willis, MD a, Walker A. Long, MD g, William R. Clarke, MD b, David Ralph, MD b, Edgar J. Caldwell, MD c, William Williams, MD c, Neil A. Ettinger, MD d, Nicholas S. Hill, MD e, Warren R. Summer, MD f, Bennett de Boisblanc, MD f, Gary Koch, PhD h, Shu Li, MS h, Linda M. Clayton, PharmD i, Maria M. Jöbsis, BA i, James W. Crow, PhD j
PPH Study Group**
See Appendix for list of participants in the PPH Study Group.
a Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
b University of Washington, Seattle, Washington, USA
c Maine Medical Center, Portland, Maine, USA
d Washington University, St. Louis, Missouri, USA
e Rhode Island Hospitals, Providence, Rhode Island, USA
f Louisiana State Medical Center, New Orleans, Louisiana, USA
g Cato Research Ltd., Durham, North Carolina, USA
h Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA
i GlaxoSmithKline, Research Triangle Park, North Carolina, USA
j United Therapeutics Inc., Chapel Hill, North Carolina, USA